POSSIBILITY OF ANTIFIBROTIC TREATMENT AFTER ELIMINATION OF HEPATITIS C VIRUS
DOI:
https://doi.org/10.11603/1681-2727.2018.1.8667Keywords:
chronic viral hepatitis C, liver fibrosis, antifibrotic treatment.Abstract
Aim. The study of the possibilities of antifibrotic treatment in patients with chronic hepatitis C after the antiviral therapy completion by appointment hepatoprotective drug biсyсlol for 3 months.
Materials and methods. The 27 patients with chronic hepatitis C without signs of cirrhosis and concomitant liver and bile duct pathology; aged 20-68 years; who completed the course of antiviral therapy and had a F2-F3 fibrosis rate in the dynamic were enrolled into the study. Analysis was performed by determination of the fibrogenesis indexes (hydroxyproline; collagen type IV) and the degree of fibrosis (fibrotest and elastography).
Сonclusions. It has been established that after successful completion of antiviral treatment in patients with hepatitis C with severe fibrosis there is no spontaneous regression of fibrotic events in the liver. Moreover; in some patients fibrosis continues to progress. In all patients with the level of fibrosis F2-F3; markedly elevated values of collagen IV and hydroxyproline in serum are observed; indicating that fibrosis is continued even after elimination of virus.
References
Lavanchy; D. (2011). Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect.; 17 (2); 107-115.
Armstrong G.L.1; Wasley A.; Simard E.P.; McQuillan G.M.; Kuhnert W.L.; & Alter M.J. (2006). The prevalence of hepatitis C virus infection in the United States; 1999 through 2002. Ann. Intern. Med.; 144; 705-714.
Mangia; A.; Santoro; R.; Copetti; M. (2013). Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J. Hepatol.; 59 (2). 21-80.
Hsu; Y.C.; Lin; J.T.; Ho; H.J.; Kao; Y.H.; & Huang; Y.T. (2014). Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology; 59(4); 1293-1302.
Faustini; A.; Colais; P.; Fabrizi; E.; Bargagli; A.M.; Davoli; M.; & Di Lallo; D. (2010). Hepatic and extra-hepatic sequelae; and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups. BMC Infect. Dis.; 10; 97.
Gospodarskiy; I.Ya.; Volinets; K.V.; & Grushko; V.V. (2013). Osobennosti lecheniya bolnykh gepatitom B i C pri soputstvuyushchiy krioglobulinemii [Features of treatment of patients with hepatitis B and C with concomitant cryoglobulinemia]. Eksperimentalnaya i klinicheckaya farmakologiya – Experimental and Clinical Pharmacology; 12; 34-37 [in Russian].
Ivanov; A.V.; Bartosch; B.; & Smirnova; O.A. (2013). HCV and oxidative stress in the liver. Viruses; 5 (2); 439-469.
Hawke; R.L.; Schrieber; S.J.; & Soule; T.A. (2010). Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J. Clin. Pharmacol.; 50 (4); 434-449.
Reddy; K.R.; Belle; S.H. (2012). Rationale; challenges; and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin. Trials.; 9 (1); 102-112.
Kolesnikova; E.V. (2014). Sovremennyy patsient s zabolevaniyem pecheni i patologiyey serdechno-sosudistoy sistemy: kakoy vybor sdelat? [A modern patient with liver disease and cardiovascular pathology: what choice should I make?]. Suchasna gastroenterologіya; 2 (76) ; 85-94 [ in Russian].
Paris; A.J.; Snapir; Z.; & Christopherson; C.D. (2011). A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1; reducing fibrogenesis. Hepatology; 54 (6); 2198-2207.
Eshraghian A. (2017). Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J. Gastroenterol.; 14; 23(42); 7495-7504.
Duong; F.H.; Christen; V.; Filipowicz; M.; & Heim; M.H. (2006). S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro . Hepatology; 43 (4); 796-806.
Lioznov; D.A.; Geivandova; N.I.; & Morozov; V.G. (2014). Otsenka effektivnosti originalnogo gepatoprotektornogo preparata Bitsiklol u bolnykh khronicheskim virusnym gepatitom C [Evaluation of the effectiveness of the original hepatoprotective drug Bycyclol in patients with chronic viral hepatitis C]. Ukrainskiy meditsinskiy zhurnal; 6 (104); 14-17 [in Russian].
Henrotin; Y.; Deberg; M.; Mathy Hartert; M.; & Deby-Dupont G. (2009). Biochemical biomarkers of oxidative collagen damage. Advances in Clinical Chemistry; 49; 31-55.
Yao; G.B.; Ji; Y.Y.; Wang; Q.H. (2002). A randomized doubleblind controlled trial of bicyclol treatment of hepatitis B. Chin. J. New Drug Clin. Rem.; 21; 457-462.
Min Li; Geng Liu. (2004). Inhibition of Fas/Fasl mRNA expression and TNF-α release in concanavalin A-induced liver in mice by bicyclol. World J. Gastroenterol.; 10; 1775-1779.
Yao; G.B.; Xu; D.Z.; & Lan; P. (2005). Efficacy and safety of Bicyclol in treatment of 2200 chronic viral hepatitis. Chin. J. New Drug Clin. Rem.; 24; 421-425.
Yi; J.; Li; W.; Xiong; Y. (2007). Protivofibroticheskiy effekt preparata Bitsiklol u patsientov s khronicheskim virusnym gepatitom B [Antifibrotic effect of Bicyclol in patients with chronic viral hepatitis B]. Bitsyklol – originalnyy preparat dlya lecheniya khronicheskikh gepatitov Bicylol is an Original Drug for the Treatment of Chronic Hepatitis [in Russian].
Hu; X.; Qiu; L.; Liu; D.; Qian; L. (2017). Acoustic Radiation Force Impulse (ARFI) Elastography for non invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med. Ultrason. 31; 19 (1); 23-31.
Downloads
Published
How to Cite
Issue
Section
License
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
